Table 3.
Proportion listed and median time-to-listing for each year for drug indications that received a CDR or pCODR listing recommendation between September 1, 2007 and August 31, 2013, before and after the establishment of the pCPA
| Jurisdiction | Number (%) of drug indications listed |
Median time-to-listing*, calendar days |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 September 2007–31 August 2008 | 1 September 2008–31 August 2009 | 1 September 2009–31 August 2010 | 1 September 2010–31 August 2011 | 1 September 2011–31 August 2012 | 1 September 2012–31 August 2013 | 1 September 2007–31 August 2008 | 1 September 2008–31 August 2009 | 1 September 2009–31 August 2010 | 1 September 2010–31 August 2011 | 1 September 2011–31 August 2012 | 1 September 2012–31 August 2013 | |
| (n=26) | (n=26) | (n=27) | (n=16) | (n=43) | (n=32) | |||||||
| British Columbia | 9 (35%) | 13 (50%) | 15 (56%) | 11 (69%) | 25 (58%) | 15 (47%) | 356 | 407 | 265 | 272 | 270 | 228 |
| Alberta | 10 (38%) | 14 (54%) | 12 (44%) | 9 (56%) | 16 (37%) | 12 (38%) | 320 | 133† | 216 | 129 | 147 | 134 |
| Saskatchewan | 10 (38%) | 16 (62%) | 15 (56%) | 9 (56%) | 27 (63%) | 18 (56%) | 140 | 106 | 290† | 93† | 149 | 139 |
| Manitoba | 8 (31%) | 9 (35%) | 14 (52%) | 7 (44%) | 25 (58%) | 13 (41%) | 278 | 567 | 993† | 463† | 352 | 252 |
| Ontario | 12 (46%) | 15 (58%) | 20 (74%) | 13 (81%) | 25 (58%) | 16 (50%) | 408 | 540 | 519 | 316 | 226 | 160 |
| New Brunswick | 12 (46%) | 16 (62%) | 13 (48%) | 8 (50%) | 25 (58%) | 13 (41%) | 179 | 147† | 148 | 217 | 284 | 252 |
| Nova Scotia | 9 (35%) | 14 (54%) | 10 (37%) | 8 (50%) | 21 (49%) | 9 (28%) | 87 | 161 | 162 | 129 | 199 | 203 |
| Prince Edward Island | 12 (46%) | 10 (38%) | 7 (26%) | 7 (44%) | 18 (42%) | 8 (25%) | 601 | 788 | 425 | 806 | 439† | 326 |
| Newfoundland and Labrador | 7 (27%) | 12 (46%) | 9 (33%) | 7 (44%) | 20 (47%) | 11 (34%) | 339 | 107† | 159 | 250 | 116 | 319 |
A drug indication was considered ‘listed’ if it had a full or restricted listing status (refer to the Methods section for further details) on the formulary of a provincial drug plan or cancer agency as of 30 April 2014.
*Excludes drug listings in any jurisdiction that occurred before a CDR or pCODR listing recommendation was issued (20 in total; 9 in British Columbia, 2 in Alberta, 2 in Saskatchewan, 1 in Manitoba, 2 in Ontario, none in New Brunswick, 1 in Nova Scotia, 1 in Prince Edward Island and 2 in Newfoundland and Labrador).
†Change compared to the preceding year was significant as per Fisher’s exact test for the proportion listed or per the Mann-Whitney U test for time-to-listing.
CDR, Common Drug Review; pCODR, pan-Canadian Oncology Drug Review; pCPA, pan-Canadian Pricing Alliance.